Versant Venture Capital — 2020 Investments
2 investments dated 2020 · listed companies and verified rows first · show all
858 Therapeutics is a clinical-stage biotechnology company developing therapies that target tumor dependencies in DNA damage response pathways for patients with advanced solid tumors.
BiotechHealthtechSan Diego, US
Stafford Jeffrey(Executive Officer, Director)James Veal(Executive Officer)Katherine Bell-McGuinn(Executive Officer)
BoardMonal Mehta(Director)Ali Behbahani(Director)
Board seatBradley J. BolzonClare Ozawa· per SEC Form D · $37.5M raise · filed Mar 2020
Co-investorsNew Enterprise Associates (NEA)Versant Ventures
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Aetna Wun Trombley(President and CEO)Amy Bachrodt(Chief Financial Officer)Chin Lee(Chief Medical Officer)Steve Staben(Chief Scientific Officer)Sofia Touami(Chief Business Officer)Karen Flick(General Counsel)
Board seatClare OzawaThomas Woiwode· per SEC Form D · $70.1M raise · filed Sep 2021
Co-investorsREDMILEVersant VenturesBAM ElevateFranklin TempletonHBM Healthcare InvestmentsInvus+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.